1 Department of Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
2 Biostatistics and Clinical Epidemiology Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Clin Trials. 2017 Oct;14(5):537-546. doi: 10.1177/1740774517722131. Epub 2017 Aug 2.
BACKGROUND/AIMS: Healthy volunteers in phase 1 clinical trials contribute to the development of safe drugs and other biologics and accept risks and burdens without anticipated health benefits from participation. Although emerging data have shown that healthy volunteers are influenced by risk, some still worry that financial incentives lead them to take on unreasonable risk. Yet little is known about healthy volunteers' preferences and how they make choices about enrolling in research studies.
We surveyed 654 healthy volunteers at the end of their participation in a phase 1 Pfizer trial in the United States, Belgium, and Singapore to examine their reported willingness to enroll in studies of different types, with various procedures, and with possible side-effects.
The majority of respondents were willing to join many kinds of studies, but fewer were willing to participate in first-in-human vaccine studies or studies of psychiatric drugs than in other study types. With regard to procedures, a substantial proportion were unwilling to participate in studies that involved invasive procedures, such as a lumbar puncture (45.4%) and bone marrow biopsy (42.3%), but willing to participate in studies with less invasive procedures such as a computed tomography scan of the heart (86.8%), magnetic resonance imaging (87.4%), and skin allergy testing (86.8%). Although there was some variation by gender and region, the majority were willing to participate in studies with side-effects like pain (80%) or nausea and vomiting (64%), but only a minority were willing to join if the research drug would result in their having a one in a million chance of death (34.4%), a small chance of kidney damage (16.7%), or influence how their mind works (23.2%; Figure 4).
Our results suggest that healthy volunteers are willing to participate in a wide range of types of phase 1 clinical trials, and express preferences for low risk and familiar studies and study procedures, preferences which are partially affected by offers of payment.
背景/目的:参加 1 期临床试验的健康志愿者为安全药物和其他生物制剂的开发做出了贡献,他们在没有预期健康获益的情况下承担了风险和负担。尽管新出现的数据表明健康志愿者受到风险的影响,但有些人仍担心经济激励会导致他们承担不合理的风险。然而,人们对健康志愿者的偏好以及他们如何选择参加研究知之甚少。
我们在美国、比利时和新加坡对 654 名参加辉瑞公司 1 期试验的健康志愿者进行了调查,以研究他们对不同类型、不同程序和可能有副作用的研究的报告意愿。
大多数受访者愿意参加多种研究,但与其他研究类型相比,他们更不愿意参加首次人体疫苗研究或精神药物研究。就程序而言,相当一部分人不愿意参加涉及侵入性程序的研究,如腰椎穿刺(45.4%)和骨髓活检(42.3%),但愿意参加侵入性较小的研究,如心脏计算机断层扫描(86.8%)、磁共振成像(87.4%)和皮肤过敏测试(86.8%)。尽管存在一些性别和地区差异,但大多数人愿意参加有副作用的研究,如疼痛(80%)或恶心和呕吐(64%),但如果研究药物导致他们有百万分之一的死亡机会(34.4%)、很小的肾脏损伤机会(16.7%)或影响思维方式(23.2%),只有少数人愿意参加(图 4)。
我们的研究结果表明,健康志愿者愿意参加广泛类型的 1 期临床试验,并对低风险和熟悉的研究和研究程序表示偏好,这些偏好部分受到支付优惠的影响。